Eli Lilly And Company ((LLY)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Eli Lilly and Company recently completed a Phase 3 study titled A Phase 3, Randomized, Double-Blind Study to Investigate the Efficacy and Safety of Once Daily Oral Orforglipron Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Insulin Glargine, With or Without Metformin and/or SGLT-2 Inhibitor. The study aimed to evaluate the safety and efficacy of orforglipron, a new oral medication for adults with Type 2 Diabetes who have not achieved adequate glycemic control with their current insulin regimen.
The intervention being tested is orforglipron, an oral drug designed to improve glycemic control in Type 2 Diabetes patients. It was compared against a placebo to assess its effectiveness and safety.
The study was interventional, with participants randomly assigned to different groups receiving either orforglipron or a placebo. It followed a parallel model with double masking to ensure unbiased results, focusing primarily on treatment outcomes.
The study began on October 26, 2023, and was last updated on October 16, 2025. These dates mark the study’s initiation and the latest update, indicating its progression and current status.
This update could positively impact Eli Lilly’s stock performance by showcasing their commitment to innovative diabetes treatments. It may also influence investor sentiment favorably, especially in comparison to competitors in the diabetes treatment market.
The study is now completed, with further details available on the ClinicalTrials portal.